과체중 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(-2031년) - 치료별, 유통 채널별, 지역별

Overweight Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

US $ 4,995 ￦ 6,937,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 11,797,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 14,721,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 과체중 치료 시장 규모는 병적 비만 인구에 대한 인식 증가, 규제 기관과 제약사 간의 전략적 제휴, 비만 관련 질환의 유병률 증가 등 다양한 요인이 복합적으로 작용하여 강력한 성장세를 보이고 있습니다. 이 시장은 2024년 340억 달러 규모에 달할 것으로 예상되며, 2031년 말에는 740억 달러에 달할 것으로 전망됩니다.

코로나19는 비만인이 다양한 건강 합병증에 취약하다는 것을 강조하면서 과체중 치료 솔루션에 대한 수요가 급증하고 있습니다. 미국심장협회가 강조한 바와 같이 심혈관 질환, 2형 당뇨병, 이상지질혈증, 수면장애, 고혈압 등의 질환은 비만과 직접적으로 관련이 있습니다. 이러한 인식으로 인해 체중 감량 솔루션을 찾는 사람들 사이에서 영양 보충제, 약물 치료, 운동, 지방 흡입과 같은 외과적 개입에 대한 선호도가 높아지고 있습니다.

미국 식품의약국(FDA)과 제약회사들의 협력으로 혁신적인 과체중 치료제의 승인 절차가 크게 빨라졌으며, 2012년 제정된 미국 식품의약국(FDA) 안전혁신법(USFDA Safety and Innovation Act)은 제약회사들이 심각한 질병에 대한 새로운 치료법을 개발할 수 있는 인센티브를 제공함으로써 시장 개발을 촉진하는 환경을 조성했습니다. 시장 개발을 촉진하는 환경을 조성하였습니다. 이러한 규제적 지원은 선진국의 좌식 생활습관 확산과 함께 향후 몇 년동안 전 세계 과체중 치료제 시장을 발전시킬 것으로 예상됩니다.

유망한 성장 궤도에도 불구하고, 시장은 높은 약물 개발 및 수술 비용과 같은 문제에 직면해 있습니다. 연구개발과 임상시험에 필요한 막대한 재정적 투자가 시장 확대에 걸림돌이 되고 있습니다. 또한, 특정 의약품과 관련된 안전성 문제로 인해 제품 회수 및 철회로 이어져 소비자의 신뢰를 떨어뜨리고 시장 성장을 저해하고 있습니다.

이 보고서는 세계 과체중 치료 시장에 대해 조사했으며, 시장 개요와 함께 치료별/유통 채널별/지역별 동향, 시장 진출기업의 경쟁 동향 등을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter의 Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 과체중 치료 시장 전망, 2018년-2031년

• 세계의 과체중 치료 시장 전망, 치료별, 금액(10억 달러), 2018년-2031년
• 세계의 과체중 치료 시장 전망, 유통 채널별, 금액(10억 달러), 2018년-2031년
• 세계의 과체중 치료 시장 전망, 지역별, 금액(10억 달러), 2018년-2031년

제4장 북미의 과체중 치료 시장 전망, 2018년-2031년

제5장 유럽의 과체중 치료 시장 전망, 2018년-2031년

제6장 아시아태평양의 과체중 치료 시장 전망, 2018년-2031년

제7장 라틴아메리카의 과체중 치료 시장 전망, 2018년-2031년

제8장 중동 및 아프리카의 과체중 치료 시장 전망, 2018년-2031년

제9장 경쟁 구도

• 제품별과 유통 채널별 히트맵
• 기업의 시장 점유율 분석, 2022년
• 경쟁 대시보드
• 기업 개요
  • Novo Nordisk A/S
  • VIVUS LLC
  • AstraZeneca
  • Currax Pharmaceuticals LLC
  • Spansules Pharmatech Pvt Ltd
  • Atkins Nutritional Inc
  • Apollo Endosurgery, Inc
  • Herbalife Nutrition Ltd.
  • SMP Nutra
  • Allurion Technologies
  • ReShape Lifesciences, Inc

제10장 부록

LSH

영문 목차

영문목차

Growing Awareness and Strategic Partnerships Drive Demand for Overweight Treatment Solutions

The global overweight treatment market is witnessing robust growth, fueled by a combination of factors including increased awareness among the morbidly obese population, strategic collaborations between regulatory bodies and drug manufacturers, and the rising prevalence of obesity-related diseases. According to the latest report by Fairfield Market Research, the market, valued at US$ 34 billion in 2024, is expected to reach a staggering valuation of US$ 74 billion by the end of 2031.

Increasing Awareness among the Morbidly Obese Population

The COVID-19 pandemic has underscored the vulnerability of obese individuals to various health complications, prompting a surge in demand for overweight treatment solutions. Diseases such as cardiovascular ailments, type II diabetes, dyslipidemia, sleep disorders, and hypertension are directly linked to obesity, as highlighted by the American Heart Association. This awareness has led to a growing inclination towards nutrition supplements, drug treatments, exercise, and surgical interventions like liposuction among individuals seeking weight loss solutions.

Cooperation between Regulatory Bodies and Drug Manufacturers

The collaboration between the U.S. Food and Drug Administration (FDA) and drug manufacturers has significantly expedited the approval process for innovative overweight treatment products. The USFDA Safety Innovations Act of 2012 has incentivized manufacturers to develop novel therapies for serious medical conditions, thereby fostering a conducive environment for market growth. This regulatory support, coupled with the increasing prevalence of sedentary lifestyles in developed nations, is expected to propel the global overweight treatment market forward in the coming years.

Challenges Hindering Market Progress

Despite the promising growth trajectory, the market faces challenges such as the high cost of drug development and surgical procedures. The substantial financial investment required for research, development, and clinical trials poses a barrier to market expansion. Moreover, safety concerns associated with certain drugs have led to product recalls and withdrawals, dampening consumer confidence and hindering market growth.

Country-wise Insights: Opportunities Abound in Key Markets

United States: With a significant share in the North American market, the U.S. remains a lucrative hub for overweight treatment solutions. The rising incidence of obesity-related diseases and increasing awareness among consumers are driving the demand for weight management resources, including dietary supplements and lifestyle modifications.

Germany: The European overweight treatment market is witnessing steady growth, with Germany emerging as a key player. High prevalence of obesity-related diseases, coupled with collaborative efforts by organizations like the German Obesity Alliance, is driving market expansion, particularly in the area of obesity treatment centers.

China: Economic growth and changing lifestyle habits have contributed to a surge in obesity rates in China. The market for overweight treatment solutions is poised for rapid expansion, with a shift towards modern interventions such as medications and surgery from traditional herbal remedies.

India: India presents immense growth opportunities in the overweight treatment market, fueled by rising obesity rates and government initiatives promoting healthy lifestyles. Initiatives such as the Ayushman Bharat Scheme and the inclusion of bariatric surgery under insurance coverage are expected to drive market growth in the country.

Competitive Landscape: Key Players Driving Innovation

Leading companies in the overweight treatment market are continuously innovating to maintain their competitive edge. Strategic initiatives such as new product launches, portfolio upgrades, and clinical research activities are commonplace. Additionally, consolidation activities through collaborations and acquisitions are enabling players to strengthen their market presence and expand their product offerings.

Key Companies Profiled:

• Novo Nordisk A/S
• VIVUS LLC
• AstraZeneca
• Currax Pharmaceuticals LLC
• Spansules Pharmatech Pvt Ltd
• Atkins Nutritional Inc
• Apollo Endosurgery, Inc
• Herbalife Nutrition Ltd.
• SMP Nutra
• Allurion Technologies
• ReShape Lifesciences, Inc
• Bariatric Solutions GmbH
• Silimed
• ENDALIS
• Districlass Medical
• Medtronic.

Key Segments Covered in Overweight Treatment Industry Research

Overweight Treatment Market by Treatment:

• Drug Treatment
  • Bupropion and Naltrexone
  • Orlistat
  • Phentermine and Topiramate
  • Liraglutide
• Others
• Supplements
• Medical Devices / Implants
  • Gastric Balloons
  • Gastric Bands
  • Stapling Devices

Overweight Treatment Market by Distribution Channel:

• Institutional Sales
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
• Retail Sales
  • Retail Pharmacy
  • Drug Stores
  • Supermarkets / Hypermarkets
  • Health & Beauty Stores
• Online Sales

Overweight Treatment Market by Region:

• North America Overweight Treatment Market
• Latin America Overweight Treatment Market
• Europe Overweight Treatment Market
• South Asia Overweight Treatment Market
• East Asia Overweight Treatment Market
• Oceania Overweight Treatment Market
• Middle East & Africa Overweight Treatment Market

Table of Contents

1. Executive Summary

• 1.1. Global Overweight Treatment Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Overweight Treatment Market Outlook, 2018 - 2031

• 3.1. Global Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1.1. Drug Treatment
      • 3.1.1.1.1.1. Bupropion and Naltrexone
      • 3.1.1.1.1.2. Orlistat
      • 3.1.1.1.1.3. Phentermine and Topiramate
      • 3.1.1.1.1.4. Liraglutide
    • 3.1.1.1.2. Others
    • 3.1.1.1.3. Supplements
    • 3.1.1.1.4. Medical Devices / Implants
      • 3.1.1.1.4.1. Gastric Balloons
      • 3.1.1.1.4.2. Gastric Bands
      • 3.1.1.1.4.3. Stapling Devices
• 3.2. Global Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. Institutional Sales
      • 3.2.1.1.1. Hospitals
      • 3.2.1.1.2. Specialty Clinics
      • 3.2.1.1.3. Ambulatory Surgical Centers
    • 3.2.1.2. Retail Sales
      • 3.2.1.2.1. Retail Pharmacy
      • 3.2.1.2.2. Drug Stores
      • 3.2.1.2.3. Supermarkets / Hypermarkets
      • 3.2.1.2.4. Health & Beauty Stores
    • 3.2.1.3. Online Sales
• 3.3. Global Overweight Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. North America
    • 3.3.1.2. Europe
    • 3.3.1.3. Asia Pacific
    • 3.3.1.4. Latin America
    • 3.3.1.5. Middle East & Africa

4. North America Overweight Treatment Market Outlook, 2018 - 2031

• 4.1. North America Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1.1. Drug Treatment
      • 4.1.1.1.1.1. Bupropion and Naltrexone
      • 4.1.1.1.1.2. Orlistat
      • 4.1.1.1.1.3. Phentermine and Topiramate
      • 4.1.1.1.1.4. Liraglutide
    • 4.1.1.1.2. Others
    • 4.1.1.1.3. Supplements
    • 4.1.1.1.4. Medical Devices / Implants
      • 4.1.1.1.4.1. Gastric Balloons
      • 4.1.1.1.4.2. Gastric Bands
      • 4.1.1.1.4.3. Stapling Devices
• 4.2. North America Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. Institutional Sales
      • 4.2.1.1.1. Hospitals
      • 4.2.1.1.2. Specialty Clinics
      • 4.2.1.1.3. Ambulatory Surgical Centers
    • 4.2.1.2. Retail Sales
      • 4.2.1.2.1. Retail Pharmacy
      • 4.2.1.2.2. Drug Stores
      • 4.2.1.2.3. Supermarkets / Hypermarkets
      • 4.2.1.2.4. Health & Beauty Stores
    • 4.2.1.3. Online Sales
• 4.3. North America Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. U.S. Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 4.3.1.2. U.S. Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.1.3. Canada Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 4.3.1.4. Canada Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Overweight Treatment Market Outlook, 2018 - 2031

• 5.1. Europe Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1.1. Drug Treatment
      • 5.1.1.1.1.1. Bupropion and Naltrexone
      • 5.1.1.1.1.2. Orlistat
      • 5.1.1.1.1.3. Phentermine and Topiramate
      • 5.1.1.1.1.4. Liraglutide
    • 5.1.1.1.2. Others
    • 5.1.1.1.3. Supplements
    • 5.1.1.1.4. Medical Devices / Implants
      • 5.1.1.1.4.1. Gastric Balloons
      • 5.1.1.1.4.2. Gastric Bands
      • 5.1.1.1.4.3. Stapling Devices
• 5.2. Europe Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Institutional Sales
      • 5.2.1.1.1. Hospitals
      • 5.2.1.1.2. Specialty Clinics
      • 5.2.1.1.3. Ambulatory Surgical Centers
    • 5.2.1.2. Retail Sales
      • 5.2.1.2.1. Retail Pharmacy
      • 5.2.1.2.2. Drug Stores
      • 5.2.1.2.3. Supermarkets / Hypermarkets
      • 5.2.1.2.4. Health & Beauty Stores
    • 5.2.1.3. Online Sales
• 5.3. Europe Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Germany Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 5.3.1.2. Germany Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.3. U.K. Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 5.3.1.4. U.K. Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.5. France Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 5.3.1.6. France Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.7. Italy Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 5.3.1.8. Italy Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.9. Turkey Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 5.3.1.10. Turkey Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.11. Russia Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 5.3.1.12. Russia Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1.13. Rest of Europe Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 5.3.1.14. Rest of Europe Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Overweight Treatment Market Outlook, 2018 - 2031

• 6.1. Asia Pacific Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1.1. Drug Treatment
      • 6.1.1.1.1.1. Bupropion and Naltrexone
      • 6.1.1.1.1.2. Orlistat
      • 6.1.1.1.1.3. Phentermine and Topiramate
      • 6.1.1.1.1.4. Liraglutide
    • 6.1.1.1.2. Others
    • 6.1.1.1.3. Supplements
    • 6.1.1.1.4. Medical Devices / Implants
      • 6.1.1.1.4.1. Gastric Balloons
      • 6.1.1.1.4.2. Gastric Bands
      • 6.1.1.1.4.3. Stapling Devices
• 6.2. Asia Pacific Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. Institutional Sales
      • 6.2.1.1.1. Hospitals
      • 6.2.1.1.2. Specialty Clinics
      • 6.2.1.1.3. Ambulatory Surgical Centers
    • 6.2.1.2. Retail Sales
      • 6.2.1.2.1. Retail Pharmacy
      • 6.2.1.2.2. Drug Stores
      • 6.2.1.2.3. Supermarkets / Hypermarkets
      • 6.2.1.2.4. Health & Beauty Stores
    • 6.2.1.3. Online Sales
  • 6.2.2. BPS Analysis/Market Attractiveness Analysis
• 6.3. Asia Pacific Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. China Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 6.3.1.2. China Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.3. Japan Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 6.3.1.4. Japan Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.5. South Korea Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 6.3.1.6. South Korea Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.7. India Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 6.3.1.8. India Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.9. Southeast Asia Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 6.3.1.10. Southeast Asia Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1.11. Rest of Asia Pacific Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 6.3.1.12. Rest of Asia Pacific Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Overweight Treatment Market Outlook, 2018 - 2031

• 7.1. Latin America Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1.1. Drug Treatment
      • 7.1.1.1.1.1. Bupropion and Naltrexone
      • 7.1.1.1.1.2. Orlistat
      • 7.1.1.1.1.3. Phentermine and Topiramate
      • 7.1.1.1.1.4. Liraglutide
    • 7.1.1.1.2. Others
    • 7.1.1.1.3. Supplements
    • 7.1.1.1.4. Medical Devices / Implants
      • 7.1.1.1.4.1. Gastric Balloons
      • 7.1.1.1.4.2. Gastric Bands
      • 7.1.1.1.4.3. Stapling Devices
• 7.2. Latin America Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 7.2.1.1. Institutional Sales
    • 7.2.1.1.1. Hospitals
    • 7.2.1.1.2. Specialty Clinics
    • 7.2.1.1.3. Ambulatory Surgical Centers
  • 7.2.1.2. Retail Sales
    • 7.2.1.2.1. Retail Pharmacy
    • 7.2.1.2.2. Drug Stores
    • 7.2.1.2.3. Supermarkets / Hypermarkets
    • 7.2.1.2.4. Health & Beauty Stores
  • 7.2.1.3. Online Sales
  • 7.2.2. BPS Analysis/Market Attractiveness Analysis
• 7.3. Latin America Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Brazil Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 7.3.1.2. Brazil Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1.3. Mexico Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 7.3.1.4. Mexico Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1.5. Argentina Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 7.3.1.6. Argentina Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1.7. Rest of Latin America Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 7.3.1.8. Rest of Latin America Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Overweight Treatment Market Outlook, 2018 - 2031

• 8.1. Middle East & Africa Overweight Treatment Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1.1. Drug Treatment
      • 8.1.1.1.1.1. Bupropion and Naltrexone
      • 8.1.1.1.1.2. Orlistat
      • 8.1.1.1.1.3. Phentermine and Topiramate
      • 8.1.1.1.1.4. Liraglutide
    • 8.1.1.1.2. Others
    • 8.1.1.1.3. Supplements
    • 8.1.1.1.4. Medical Devices / Implants
      • 8.1.1.1.4.1. Gastric Balloons
      • 8.1.1.1.4.2. Gastric Bands
      • 8.1.1.1.4.3. Stapling Devices
• 8.2. Middle East & Africa Overweight Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. Institutional Sales
      • 8.2.1.1.1. Hospitals
      • 8.2.1.1.2. Specialty Clinics
      • 8.2.1.1.3. Ambulatory Surgical Centers
    • 8.2.1.2. Retail Sales
      • 8.2.1.2.1. Retail Pharmacy
      • 8.2.1.2.2. Drug Stores
      • 8.2.1.2.3. Supermarkets / Hypermarkets
      • 8.2.1.2.4. Health & Beauty Stores
    • 8.2.1.3. Online Sales
  • 8.2.2. BPS Analysis/Market Attractiveness Analysis
• 8.3. Middle East & Africa Overweight Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. GCC Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 8.3.1.2. GCC Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1.3. South Africa Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 8.3.1.4. South Africa Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1.5. Egypt Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 8.3.1.6. Egypt Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1.7. Nigeria Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 8.3.1.8. Nigeria Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1.9. Rest of Middle East & Africa Overweight Treatment Market by Treatment, Value (US$ Bn), 2018 - 2031
    • 8.3.1.10. Rest of Middle East & Africa Overweight Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. By Product vs by Distribution Channel Heatmap
• 9.2. Company Market Share Analysis, 2022
• 9.3. Competitive Dashboard
• 9.4. Company Profiles
  • 9.4.1. Novo Nordisk A/S
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Therapy Portfolio
    • 9.4.1.3. Financial Overview
    • 9.4.1.4. Business Strategies and Development
  • 9.4.2. VIVUS LLC
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Therapy Portfolio
    • 9.4.2.3. Financial Overview
    • 9.4.2.4. Business Strategies and Development
  • 9.4.3. AstraZeneca
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Therapy Portfolio
    • 9.4.3.3. Financial Overview
    • 9.4.3.4. Business Strategies and Development
  • 9.4.4. Currax Pharmaceuticals LLC
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Therapy Portfolio
    • 9.4.4.3. Financial Overview
    • 9.4.4.4. Business Strategies and Development
  • 9.4.5. Spansules Pharmatech Pvt Ltd
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Therapy Portfolio
    • 9.4.5.3. Financial Overview
    • 9.4.5.4. Business Strategies and Development
  • 9.4.6. Atkins Nutritional Inc
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Therapy Portfolio
    • 9.4.6.3. Financial Overview
    • 9.4.6.4. Business Strategies and Development
  • 9.4.7. Apollo Endosurgery, Inc
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Therapy Portfolio
    • 9.4.7.3. Financial Overview
    • 9.4.7.4. Business Strategies and Development
  • 9.4.8. Herbalife Nutrition Ltd.
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Therapy Portfolio
    • 9.4.8.3. Financial Overview
    • 9.4.8.4. Business Strategies and Development
  • 9.4.9. SMP Nutra
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Therapy Portfolio
    • 9.4.9.3. Financial Overview
    • 9.4.9.4. Business Strategies and Development
  • 9.4.10. Allurion Technologies
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Therapy Portfolio
    • 9.4.10.3. Financial Overview
    • 9.4.10.4. Business Strategies and Development
  • 9.4.11. ReShape Lifesciences, Inc
    • 9.4.11.1. Company Overview
    • 9.4.11.2. Therapy Portfolio
    • 9.4.11.3. Financial Overview
    • 9.4.11.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

관련자료